About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Experimental Drug Reduces Second Stroke

by Sheela Philomena on February 2, 2012 at 12:26 PM
Font : A-A+

 Experimental Drug Reduces Second Stroke

In patients with brain aneurysm, clazosentan - an experimental drug decreases the risk of blood vessel spasm, reveals research.

In patients with a subarachnoid hemorrhage, even after the burst weak spot in the vessel is closed, irritation from the initial bleeding can cause blood vessels to constrict, cutting off normal blood supply and resulting in even more brain damage. This is often called a "second stroke." The vessel constriction is called angiographic vasospasm (VSP), which can occur about three to 14 days after aneurysm rupture.

Advertisement

"We don't have very effective treatments for this complication," said R. Loch Macdonald, M.D., study lead author and head of neurosurgery at St. Michael's Hospital, University of Toronto in Ontario, Canada. "The treatment in use now is very expensive and risky and doesn't work very well, and about half of the patients suffer permanent problems from it."

The Effect of Clazosentan on Clinical Outcome after Aneurysmal Subarachnoid Hemorrhage and Endovascular Coiling (CONSCIOUS-3) Study included 571 patients with a ruptured aneurysm treated with an endovascular coil, a device used to repair the ruptured blood vessel.
Advertisement

Researchers divided patients into three groups, each given either a placebo, 5 mg clazosentan or 15 mg clazosentan. They halted CONSCIOUS-3 prematurely after patients in CONSCIOUS-2 (a trial of patients whose ruptured aneurysm was secured by coiling), which ran simultaneously, showed no benefit from the drug.

In CONSCIOUS-3, 27 percent of patients on placebo died, had vasospasm-related blood clots or neurological problems, or had rescue therapy to treat vasospasm, compared with 24 percent in the 5 mg/h and 15 percent in the 15 mg/h clazosentan groups. The odds of this combined endpoint were 53 percent lower at the higher clazosentan dose than with a placebo.

"Despite having less than half of the intended patients in the study, we were encouraged to see that at a high dose there was a significant reduction in vasospasm in patients initially treated with endovascular coiling," Macdonald said.

In other findings:
  • Neurological deficits decreased with increasing clazosentan dose.
  • Rescue therapy was three times less in patients with 15 mg/h clazosentan (7 percent) compared to those receiving placebo (21 percent).
  • The occurrence of poor functional outcome or deaths within 12 weeks was not significantly different between placebo and medication groups.
  • Patients receiving clazosentan had more lung complications, anemia and low blood pressure than those on placebo.


"The data suggests that the drug is effective at reducing delayed cerebral ischemia, its side effect profile is acceptable, and further studies with different doses, administration regimens, and the avoidance of other vasodilators may allow an improvement in outcome to be demonstrated," Macdonald said.

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Get Involved and Stand Up for Human Rights on Human Rights Day 2022
Coronary Artery Bypass Grafting
Macronutrients Calculator for Weight Loss
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Diet Lifestyle and Heart Disease Mitral Valve Stenosis And Mitral Valve Replacement Congenital Heart Disease Signature Drug Toxicity Stress and the Gender Divide Stroke Facts Stroke Hyperventilation How to Deal with a Stroke 

Most Popular on Medindia

Blood - Sugar Chart How to Reduce School Bag Weight - Simple Tips Pregnancy Confirmation Calculator Hearing Loss Calculator Drug - Food Interactions Blood Pressure Calculator Sinopril (2mg) (Lacidipine) Turmeric Powder - Health Benefits, Uses & Side Effects Blood Donation - Recipients Vent Forte (Theophylline)
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Experimental Drug Reduces Second Stroke Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests